Collaborative Project to Develop Next-Generation Cell Platform for Viral Vector Production Receives £1.1 Million Grant from Innovate UK & NRC

In a ground-breaking collaboration, leading biotechnology companies and research organizations in UK and Canada are entering into a R&D project jointly funded by a £1.1 million grant from Innovate UK (part of UK Research and Innovation) and the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP). The project is led by VVector Bio and joined by the NRC, Revvity and Abselion.

Cell and Gene Therapies hold immense promise for curing a myriad of diseases, yet their widespread adoption is impeded by manufacturing limitations. Current methods face hurdles such as low yields, poor scalability, high costs, and quality testing challenges. Traditional approaches have yielded minimal improvements, requiring a fresh perspective.

In response, the project consortium has devised a multifaceted strategy to revolutionize viral vector manufacturing. Central to this endeavour is the genetic modification of the widely used HEK-293 cell line. By meticulously analysing the cell line's genome and transcriptome under producing and non-producing conditions, researchers aim to identify genes directly impacting viral vector yields and quality. Combined with an innovative approach to manufacturing and process monitoring empowered by on-line process analytics, the project seeks to disrupt the existing viral vector production process.

"This project represents a paradigm shift towards improving viral vector manufacturing yields," remarked Alina Venereo Sanchez, CEO of VVector Bio. "By integrating genomics, epigenomics, transcriptomics, metabolomics and new ways of directly integrating analytics into production, we're poised to unlock unprecedented production capabilities."

The project builds upon NRC’s expertise in biomanufacturing and viral vector production. "Our past achievements underscore the feasibility of our approach, and we anticipate significant enhancements" emphasized Aziza Manceur at NRC.

“Revvity is excited to be part of this consortium” commented Bryan Kipp, Senior Vice President, Technology & Licensing, Revvity. “Its goal aligns with our mission to help our customers overcome the challenges they face in accelerating the creation of next-generation therapies for patients. Together, we aim to drive innovation in the cell and gene manufacturing process, which will, in turn, help get life-changing therapies in the hands of patients that need them sooner.”

“Process optimization through at-line & on-line analytics is key to redefining viral vector manufacturing.” noted Ruizhi Wang, CEO of Abselion. “This project is the ultimate opportunity to showcase how it can accelerate development and result in more efficient and robust production of the next generation of therapeutics.”

The collaboration includes organizations from both Canada and the UK. It is funded as part of the “Canada-UK: Biomanufacturing of Biologics and Advanced Therapies” programme, which is jointly funded by Innovate UK and the National Research Council of Canada Industrial Research Assistance Program. The goal of the programme is to stimulate the development and implementation of innovative technologies in biomanufacturing.

About VVector Bio

VVector Bio is a company based in Montreal, Canada developing disruptive technologies to increase viral vector yields and offering R&D manufacturing services of viral vectors to accelerate cell and gene therapy clinical translation. Learn more at www.vvectorbio.com

About NRC IRAP

The National Research Council Canada is the primary national agency of the Government of Canada dedicated to science and technology research and development. It is the largest federal research and development organization in Canada. The Industrial Research Assistance Program (NRC IRAP) is Canada's leading innovation assistance program for small and medium-sized businesses. Learn more at www.nrc.canada.ca

About Revvity

At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

With 2023 revenue of more than $2.7 billion and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries. Learn more at www.revvity.com

About Innovate UK

Innovate UK, part of UK Research and Innovation, is the UK’s innovation agency. Our mission is to help companies to grow through their development and commercialisation of new products, processes and services, supported by an outstanding innovation ecosystem that is agile, inclusive and easy to navigate. Learn more at www.ukri.org/councils/innovate-uk

About Abselion

Abselion is a Cambridge, UK based company developing automated instrumentation for at-line and on-line analytics for the production of biologics, such as antibodies and viral vectors. Pioneering the proprietary Redox-Electrochemical-Detection (RED) Technology, Abselion seeks to streamline and accelerate process analytics in biopharma production. Learn more at www.abselion.com or follow us on LinkedIn @abselion.